T-Therapeutics closed a $133 million Series B to take its two lead experimental medicines into human trials, the Cambridge, England-based biotech announced November 5. Advent Life Sciences and British Business Bank co-led the round, which is intended to fund initial clinical proof of concept in cancer and autoimmune disease.
The company develops drugs that recruit T cells to kill cancer cells or disease-driving immune cells. Its engineered T cell receptors recognize short protein fragments from target cells, including fragments of proteins inside those cells, according to its technical descriptions.
That expands the pool of potential targets compared with conventional antibody approaches, the company says. Its cancer program is designed for use across several solid tumor types; its autoimmune program aims to reduce chronic inflammation by selectively removing the immune cells responsible.
The new round is larger than T-Therapeutics’ entire $91 million Series A, which included a $32 million extension announced in November 2025. Johnson & Johnson’s JJDC and Eli Lilly joined as new investors in the Series B, alongside Samsara BioCapital and M-Ventures. All major existing shareholders also participated.
T-Therapeutics also appointed Kirsty Crame as chief development officer to oversee clinical development. She previously served as chief medical officer at Curatis and led early clinical programs at Medigene and Gadeta.